Chokri Ben Lamine: Platelet Subpopulations and Targeted Therapies Across Evidence Levels
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Study Stage / Evidence Level – Platelet Subpopulation – Targeted Therapies
Reversible P2Y12 inhibitors (ticagrelor / cangrelor)
- Stage: Phase III (established clinical practice)
- PLATO trial – robust RCT evidence – guideline standard in ACS
- Highest level evidence (Class I recommendation in cardiology guidelines)
GPVI inhibitors (glenzocimab, revacept)
- Stage: Phase II clinical trials
- PCI studies – good safety (decreased bleeding)
- Efficacy signal modest – no reduction in MI yet
- Promising but NOT standard of care
PI3K inhibition (LY294002)
- Stage: Preclinical / experimental
- Mechanistic targeting only
- No clinical application currently
COX-2 targeting / aspirin adjustment
- Stage: Mixed clinical data (small trials / observational)
- No consistent benefit – not guideline recommended
- Conceptual explanation for aspirin resistance
Platelet–immune axis (VEGF / PDGF / αIIbβ3 in cancer)
- Stage: Early clinical / exploratory (e.g., APOLLO study)
- Signal for improved outcomes with ICI combinations
- Hypothesis-generating – not standard oncology practice
S100A8/A9 inhibitors (ABR-215757)
- Stage: Preclinical models
- Demonstrated decreased RP-driven thrombosis
- No human outcome trials yet
SGLT2 inhibitors (indirect platelet modulation)
- Stage: Phase III cardiovascular outcome trials (indirect evidence)
- Proven decreased CV events – platelet benefit inferred
- Not platelet-specific indication but clinically relevant
Summary hierarchy (very high yield)
Phase III / Standard: Ticagrelor / Cangrelor
Phase II / Emerging: GPVI inhibitors
Preclinical / Experimental:
- PI3K inhibitors
- S100A8/A9 inhibitors
Hypothesis / Mixed evidence:
- COX-2 targeting
- Platelet–immune modulation
Clinical pearl
- Only P2Y12 reversible inhibitors currently translate platelet subpopulation biology into routine practice.
- Everything else is precision medicine pipeline (future hematology/cardiology integration).”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Jul 3, 2026, 05:55New Evidence Supports Chromogenic Assays After Hemophilia A Gene Therapy – JTH
-
Jul 3, 2026, 05:50Jacopo Parizzi: Roche’s Non-Malignant Hematology Team Is Looking Ahead to 2027
-
Jul 3, 2026, 05:25Brian A Beh: A New Approach from The George Institute for Global Health Could Transform Stroke Care Before Hospital Arrival
-
Jul 3, 2026, 05:22Deirdre Finnigan: New Insights into Red Blood Cell Biomechanics in Cancer-Associated Anemia
-
Jul 3, 2026, 05:15Danielle Boyle: Collaboration Across Borders Is Helping Shape the Future of ITP Care
-
Jul 3, 2026, 05:05Claire McIvor: One Year at the Stroke Association and Grateful for a Workplace That Made It Possible
-
Jul 2, 2026, 23:11Michael Makris: Join The Cancer Associated Thrombosis Workshop at ISTH 2026
-
Jul 2, 2026, 21:54Rob Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy